Supplementary Online Content
|
|
- Dwain Dawson
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 0;7():8-5. eappendix. Supplementary cost-effectiveness analysis ereferences etable. Cost and Utility Parameters, Values, and Plausible Ranges etable. Diagnostic performance of serological tests test combinations efigure. Model Structure efigure. Sensitivity Analysis: Effect of Change in Baseline Gastrointestinal Bleed Risk for a 55-Year-Old Man With a 0-Year, 0% CHD Risk. A. Aspirin Versus No Treatment. B. Aspirin+PPI Versus Aspirin Alone efigure. Sensitivity Analysis: Effect of Change in Baseline Gastrointestinal Bleed Risk for a 65-Year-Old Man With a 0-Year, 0% CHD Risk. A. Aspirin Versus No Treatment. B. Aspirin+PPI Versus Aspirin Alone efigure. Sensitivity Analysis: Effect of Change in Risk of Gastrointestinal Bleed Mortality for a 5-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone efigure 5. Sensitivity Analysis: Effect of Change in Annual Price of PPI for a 5-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone efigure 6. Probabilistic Sensitivity Analysis: a 5-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin Versus No Treatment Cost-effectiveness Acceptability Curve efigure 7. Probabilistic Sensitivity Analysis: a 65-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin Versus No Treatment. A: Scatter Plot. B. Cost-effectiveness Acceptability Curve efigure 8. Probabilistic Sensitivity Analysis: a 65-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone This supplementary material has been provided by the authors to give readers additional information about their work. 00 American Medical Association. All rights reserved. Downloaded From: on 0/07/09
2 eappendix Costs Healthy men with and without previous gastrointestinal bleed incurred one outpatient physician visit per year. Acute event health states (angina, myocardial infarction, stroke, and gastrointestinal bleed) included the cost of hospitalization for the respective event as estimated from Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, which contains a national representative sample of hospital inpatient stays. The Healthcare Cost and Utilization Project, Nationwide Inpatient Sample is compiled by the Agency for Healthcare Research and Quality and contains a national representative sample of hospital inpatient stays for a variety of International Classification of Diseases 9th Revision, Clinical Modification and Healthcare Common Procedure Coding System codes. Men in these health states incurred one annual outpatient physician visit and post-event costs for the remaining months within the health state. Annual costs for post-event health states (post angina, post myocardial infarction, and post stoke) were obtained from published literature. Once a man had a cardiovascular disease event, he was assumed to have four additional visits a year. Cost of generic aspirin (8 mg per day) and omeprazole (0 mg per day) were estimated from publicly available drug store pricing ( Details on costs are presented in etable. Utilities The utilities for the model were drawn from the literature and are shown in etable. -6 Results Results are presented in etable and efigures through 8. Acceptability curves for aspirin +PPI versus aspirin alone were not shown for 5 year old and 65 year men because no incremental costeffectiveness ratios between 0 and $50,000 were generated as within the probabilistic sensitivity analyses. 00 American Medical Association. All rights reserved. Downloaded From: on 0/07/09
3 REFERENCES. Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women. Arch Intern Med. 007;67: Augustovski FA, Cantor SB, Thach CT, Spann, SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 998;: Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk. Arthritis Rheum. 005;5(): Nease RF, Kneeland T, O Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA. 995;7: Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Circulation. 995;9: Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 99;: Walgreen s. Aspirin pricing Available at: Accessed September 6, American Medical Association (AMA). Current procedural terminology. CPT 00. Chicago, IL: AMA Press; Ingenix, Inc. The essential RBRVS: a comprehensive listing of RBRVS values for CPT and HCPCS codes. St. Anthony Publishing; HCUPnet. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 006. Available at: Accessed June 7, American Medical Association. All rights reserved. Downloaded From: on 0/07/09
4 Friedman B, La Mare J, Andrews R, et al. Assuming an average cost to charge ratio of 0.5: practical options for estimating cost of hospital inpatient stays. J Health Care Finance. 00;9:-.. US Dept of Labor, US Bureau of Labor Statistics. US city average, not seasonally adjusted medical care. Available at: Accessed April 0, Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 998;8: etable. Cost and Utility Parameters, Values, and Plausible Ranges Parameter Cost Data (annual) Base-Case Value (Range) Source or Assumption Aspirin $.99 8 mg daily 7 Generic PPI $ mg of omeprazole daily 7 Outpatient physician visit $6.76 CPT code 990 8,9 Health State Costs (Annual) Healthy $6.76 Assumed to be outpatient physician visit a year 00 American Medical Association. All rights reserved. Downloaded From: on 0/07/09
5 Gastrointestinal bleed $, Gastrointestinal bleed ICD-9 codes: 5.00, 5.0, 5.0, 5., 5.00, 5.0, 5.0, 5., 5.00, 5.0, 5.0, 5., 5.00, 5.0, 5.0, 5., 55.0, 55., 55., 55., 55., 55.5, Post gastrointestinal bleed $6.76 Assumed to similar to healthy patient 00 American Medical Association. All rights reserved. 5 Downloaded From: on 0/07/09
6 etable (continued). Cost and Utility Parameters, Values, and Plausible Ranges Parameter Base-Case Value (Range) Source or Assumption Angina $,7 Angina ICD-9 codes:.9 0- Post angina $5,99, Stroke $,706 Stroke ICD-9 codes: 0.xx,.xx,.0,.,.,.,.,.5,.6,.7,.8,.9,.0,.,.,.,.5,.6,.7,.8,.9, 6.xx 0- Post stroke $,85, Myocardial infarction $,65 Myocardial infarction ICD-9 codes: 0.xx 0- Post myocardial infarction $,590, 00 American Medical Association. All rights reserved. 6 Downloaded From: on 0/07/09
7 etable (continued). Cost and Utility Parameters, Values, and Plausible Ranges Parameter Utility Data Base-Case Value (Range) Source or Assumption Healthy.000 Gastrointestinal bleed 0.9 (95% CI: 0.880,.000) Post gastrointestinal bleed.000 Assumption Dyspepsia Angina Post angina Stroke (95% CI: 0.997,.000) 0.99 (95% CI: 0.9,.000) (95% CI: 0.997,.000) 0.60 (95% CI: 0.80, 0.80) Post stroke Myocardial infarction Post myocardial infarction (95% CI: 0.80, 0.90) 0.90 (95% CI: 0.860, 0.960) 6 6 Healthy.000 CI = confidence interval; CPT = current procedural terminology; HCUP = Healthcare Cost and Utilization Project; ICD-9 = International Classification of Diseases, 9th Revision, Clinical Modification; PPI = proton pump inhibitor. 00 American Medical Association. All rights reserved. 7 Downloaded From: on 0/07/09
8 etable. Effect of 0-Year CHD Risk on Lifetime Cost-Utility Ratio for 5-Year-Old Men Using Risk of MI and Stroke From Berger et al. (006) High- Low Low-Moderate Moderate Moderate High Very High (.5%) Risk (5.0%) Risk (7.5%) Risk (0%) Risk (5%) Risk (5%) Risk Results for 5-Year-Old Men Aspirin vs. no $7,008 More effective, More effective, More effective, More effective, More effective, treatment less costly less costly less costly less costly less costly Aspirin+PPI vs. $89,707 $68,688 $99,0 $9,567 $67,7 $,556 aspirin alone Results for 65-Year-Old Men Aspirin vs. no treatment $,977 $,9 $5 More effective, less costly More effective, less costly Aspirin+PPI vs. $8, $,6 $8,85 $8,09 $77,7 aspirin alone CHD = coronary heart disease; PPI = proton pump inhibitor American Medical Association. All rights reserved. Downloaded From: on 0/07/09
9 efigure. Model Structure a a Men can progress from any health state to death. 9 Downloaded From: on 0/07/09
10 efigure. Sensitivity Analysis: Effect of Change in Baseline Gastrointestinal Bleed Risk for a 55-Year-Old Man With a 0-Year, 0% CHD Risk efigure A. Aspirin Versus No Treatment 0 Downloaded From: on 0/07/09
11 efigure B. Aspirin+PPI Versus Aspirin Alone CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-year. Downloaded From: on 0/07/09
12 efigure. Sensitivity Analysis: Effect of Change in Baseline Gastrointestinal Bleed Risk for a 65-Year-Old Man With a 0-Year, 0% CHD Risk efigure A. Aspirin Versus No Treatment Downloaded From: on 0/07/09
13 efigure B. Aspirin+PPI Versus Aspirin Alone CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-year. Downloaded From: on 0/07/09
14 efigure. Sensitivity Analysis: Effect of Change in Risk of Gastrointestinal Bleed Mortality for a 5-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone 5 CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-year. Downloaded From: on 0/07/09
15 efigure 5. Sensitivity Analysis: Effect of Change in Annual Price of PPI for a 5- Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone CHD = coronary heart disease; PPI = proton pump inhibitor; QALY = quality-adjusted life-year. 5 Downloaded From: on 0/07/09
16 efigure 6. Probabilistic Sensitivity Analysis: a 5-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin Versus No Treatment Cost-effectiveness Acceptability Curve CHD = coronary heart disease; QALY = quality-adjusted life-year. 6 Downloaded From: on 0/07/09
17 efigure 7. Probabilistic Sensitivity Analysis: a 65-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin Versus No Treatment efigure 7A: Scatter Plot 5 7 Downloaded From: on 0/07/09
18 efigure 7B. Cost-effectiveness Acceptability Curve CHD = coronary heart disease; QALY = quality-adjusted life-year. 8 Downloaded From: on 0/07/09
19 efigure 8. Probabilistic Sensitivity Analysis: a 65-Year-Old Man With a 0-Year, 0% CHD Risk Aspirin+PPI Versus Aspirin Alone 5 9 Downloaded From: on 0/07/09
Setting The setting was primary care. The economic study was carried out in the USA.
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Pignone M, Earnshaw S, Tice J A, Pletcher M J Record Status This is a critical
More informationORIGINAL INVESTIGATION. Michael Pignone, MD, MPH; Stephanie Earnshaw, PhD; Mark J. Pletcher, MD, MPH; Jeffrey A. Tice, MD
ORIGINAL INVESTIGATION Aspirin for the Primary Prevention of Cardiovascular Disease in Women A Cost-Utility Analysis Michael Pignone, MD, MPH; Stephanie Earnshaw, PhD; Mark J. Pletcher, MD, MPH; Jeffrey
More informationSupplementary Online Content
Supplementary Online Content Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.
More informationClopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation
More informationSupplementary Online Content
Supplementary Online Content Arrieto A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationDiabetes is a major risk factor for cardiovascular
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes RUI LI, PHD 1 PING ZHANG, PHD 1 1 LAWRENCE E. BARKER,
More informationSupplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
More informationSetting The setting was primary care. The economic study was carried out in the UK.
Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationCost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets
More informationSetting The setting was the community. The economic study was carried out in the USA.
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Yun H R, Bae S C Record
More informationLink between effectiveness and cost data The effectiveness and cost data came from the same sample of patients and were prospectively evaluated.
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Raikou M, McGuire A, Colhoun
More informationeappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs
eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal Anti-Inflammatory Drugs Nonselective nonsteroidal anti-inflammatory drugs Diclofenac, etodolac, flurbiprofen, ketorolac, ibuprofen,
More informationEffectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K Record Status This is a critical abstract of an economic evaluation that meets
More informationInvestor Conference Call
Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery
More informationClopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No.
MTA REPORT Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90) ADDENDUM 2 This report was commissioned by the NIHR HTA
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
A cost-utility analysis of clopidogrel in patients with non-st-segment-elevation acute coronary syndromes in the UK Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R Record
More informationSupplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More informationSupplementary Online Content
Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic
More informationSupplementary Online Content
Supplementary Online Content Guimarães PO, Krishnamoorthy A, Kaltenbach LA, et al. Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationAmerican Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease
American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationHealth technology Abciximab use in high-risk patients undergoing percutaneous transluminal coronary angioplasty.
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in highrisk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study van Hout B A, Bowman L,
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationSupplementary Online Content
Supplementary Online Content Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. doi:10.1001/jama.2014.8266
More informationORIGINAL INVESTIGATION. Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
ORIGINAL INVESTIGATION Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack François P. Sarasin, MD; Jean-Michel Gaspoz, MD, MSc; Henri Bounameaux,
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationSupplementary Online Content
Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant
More informationSupplementary Online Content
Supplementary Online Content Deslée G, Mal H, Dutau H, et al; REVOLENS Study Group. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical
More informationAnn Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161
Ann Rheum Dis 2017;76:1642 1647. doi:10.1136/annrheumdis-2016-211066 Lin, Wan-Ting 2018/05/161 Introduction We and others have previously demonstrated an increased risk of acute coronary syndrome (ACS)
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationSetting The setting was secondary care. The economic study appears to have been conducted in the UK.
One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial Weintraub W S, Mahoney E M, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara
More informationSource of effectiveness data The effectiveness evidence came from a review of published studies and the authors' assumptions.
Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond Tice J A, Ross E, Coxson P G, Rosenberg
More informationCost-utility evaluation of influenza vaccination in patients with existing coronary heart diseases in Thailand
Asian Biomedicine Vol. 7 No. 3 June 2013; 425-435 Brief communication (Original) DOI: 10.5372/1905-7415.0703.196 Cost-utility evaluation of influenza vaccination in patients with existing coronary heart
More informationTYPE 2 DIABETES IS A MAJOR
ORIGINAL CONTRIBUTION Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes The CDC Diabetes Cost-effectiveness Group
More informationSupplementary Online Content
Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online
More informationSupplementary Online Content
Supplementary Online Content Pham B, Stern A, Chen W, et al. Preventing pressure ulcers in long-term care: a costeffectiveness analysis. Arch Intern Med. Published online September 26, 2011. doi:10.1001/archinternmed.2011.473
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationSetting The setting was primary care. The economic study was carried out in the UK and the USA.
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension
More informationSupplementary Online Content
Supplementary Online Content Gomes T, Redelmeier DA, Juurlink DN, et al. Opiod dose and risk of road trauma in Canada: a populationbased study. JAMA Intern Med. Published online January 14, 2013. doi:10.1001/2013.jamainternmed.733.
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationQuality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationCoronary Heart Disease
Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has
More informationSupplementary Online Content
Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2013 June 24; 173(12): 1150 1151. doi:10.1001/jamainternmed.2013.910. SSRI Use, Depression and Long-Term Outcomes
More informationSUPPLEMENTARY DATA. Table of Contents
Table of Contents Supplemental Figure S1. Kaiser Permanente Diabetes Registry Patient Flow Diagram Supplemental Table S1. Diagnostic and procedure codes and frequency of events during follow-up for outcomes
More informationSupplementary Online Content
Supplementary Online Content Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for highrisk bleeding ulcers: systematic review and meta-analysis. JAMA Intern Med. Published
More informationCardiovascular diseases (CVD), including myocardial
Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease Tzeyu L. Michaud, PhD; Jean Abraham, PhD; Hawre Jalal, MD, PhD; Russell V. Luepker, MD,
More informationCost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention
Alimentary Pharmacology and Therapeutics Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention S. D. Saini*,, A. M.
More informationSupplementary Online Content
Supplementary Online Content Callaghan B, McCammon R, Kerber K, Xu X, Langa KM, Feldman E. Tests and expenditures in the initial evaluation of peripheral neuropathy. Arch Intern Med. 2012;172(2):127-132.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding 1.1 Short title Acute upper GI bleeding
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY
ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY Braden Te Ao, Ph.D. Centre for Health Services Research & Policy, University of Auckland, National
More informationHeart Attack Readmissions in Virginia
Heart Attack Readmissions in Virginia Schroeder Center Statistical Brief Research by Mitchell Cole, William & Mary Public Policy, MPP Class of 2017 Highlights: In 2014, almost 11.2 percent of patients
More informationSupplementary Online Content
Supplementary Online Content Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170(21):1909-1917. eappendix.
More informationSupplementary Online Content
Supplementary Online Content Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationSetting The setting was secondary care. The study was carried out in the UK, with emphasis on Scottish data.
Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan
More informationSupplementary Online Content
Supplementary Online Content Wolters FJ, Li L, Gutnikov SA, Mehta Z, Rothwell PM. Medical attention seeking after transient ischemic attack and minor stroke in relation to the UK Face, Arm, Speech, Time
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationAbstract. Background. Methods
RESEARCH ARTICLE Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C- Reactive
More informationAm J Gastroenterol 2010;105:
ACCF/ACG/AHA 2010 Expert Consensus Document Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationProton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel
Proton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel Dr.A.K.M. Aminul Hoque Assoc. Prof. of Medicine. Dhaka Medical College. Clopidogrel Metabolism Clopidogrel is an inactive
More informationCan i take indomethacin with aspirin
Can i take indomethacin with aspirin The Borg System is 100 % Can i take indomethacin with aspirin People who take nonsteroidal anti-inflammatory drugs (NSAIDs) (other than aspirin ) such as indomethacin
More informationSupplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationSupplementary Online Content
Supplementary Online Content Pincus D, Ravi B, Wasserstein D. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. doi: 10.1001/jama.2017.17606 eappendix
More informationRESEARCH. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands 2 Department of Vascular Medicine, University Medical Center Utrecht 3 Center for Prevention
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationPREVENTING NSAID INDUCED GI COMPLICATIONS: AN ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES IN CANADA. February 13, 2007
PREVENTING NSAID INDUCED GI COMPLICATIONS: AN ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES IN CANADA February 13, 2007 Canadian Agency for Drugs and Technologies in Health (CADTH) TABLE OF CONTENTS 1.0
More informationHelicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J
Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J Record Status This is a critical abstract of an economic
More informationTennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center
Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center 2006 Tennessee Department of Health 2006 ACKNOWLEDGEMENTS CONTRIBUTING
More informationEconomic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women
Y O R K Health Economics C O N S O R T I U M NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women Supplementary Report
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION
More informationSupplementary Online Content
Supplementary Online Content Song Z, Ayanian JZ, Wallace J, He Y, Gibson TB, Chernew ME. Unintended consequences of eliminating Medicare payments for consultations. JAMA Intern Med. Published online November
More informationBurden of Hospitalizations Primarily Due to Uncontrolled Diabetes: Implications of Inadequate Primary Health Care in the United States
Diabetes Care In Press, published online February 8, 007 Burden of Hospitalizations Primarily Due to Uncontrolled Diabetes: Implications of Inadequate Primary Health Care in the United States Received
More informationSupplementary Online Content
Supplementary Online Content Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population.
More informationSupplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
More informationSupplementary Online Material
Supplementary Online Material Collet T-H, Gussekloo J, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med.
More informationCost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T Record Status This is a critical abstract of an economic
More informationA Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury
A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly
More informationSetting The setting was the Walter Reed Army Medical Center. The economic study was carried out in the USA.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationSupplementary Online Content
Supplementary Online Content Lapergue B, Blanc R, Gory B, et al; ASTER Trial Investigators. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More information